Targeting Glycogen Synthase Kinase‐3 β for Therapeutic Benefit against Oxidative Stress in Alzheimer′s Disease: Involvement of the Nrf2‐ARE Pathway
International Journal of Alzheimer’s Disease · 2011-01 · 2011 (1)
DOI: 10.4061/2011/985085 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Alzheimer’s Disease, online erschienen am 02.05.2011. Verfasst von Katja Kanninen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Academy of Finland, Finnish Cultural Foundation, Orion-Farmos Research Foundation.
Themen: Demenz
Abstract (Originalsprache)
Specific regions of the Alzheimer′s disease (AD) brain are burdened with extracellular protein deposits, the accumulation of which is concomitant with a complex cascade of overlapping events. Many of these pathological processes produce oxidative stress. Under normal conditions, oxidative stress leads to the activation of defensive gene expression that promotes cell survival. At the forefront of defence is the nuclear factor erythroid 2‐related factor 2 (Nrf2), a transcription factor that regulates a broad spectrum of protective genes. Glycogen synthase kinase‐3 β (GSK‐3 β ) regulates Nrf2, thus making this kinase a potential target for therapeutic intervention aiming to boost the protective activation of Nrf2. This paper aims to review the neuroprotective role of Nrf2 in AD, with special emphasis on the role of GSK‐3 β in the regulation of the Nrf2 pathway. We also examine the potential of inducing GSK‐3 β by small‐molecule activators, dithiocarbamates, which potentially exert their beneficial therapeutic effects via the activation of the Nrf2 pathway.
Autor:innen und Institutionen
- Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
Förderung
- Academy of Finland
- Finnish Cultural Foundation
- Orion-Farmos Research Foundation
- Sigrid Juselius Foundation
Zitieren
APA
Kanninen, K., White, A. R., Koistinaho, J., & Malm, T. (2011). Targeting Glycogen Synthase Kinase‐3 β for Therapeutic Benefit against Oxidative Stress in Alzheimer′s Disease: Involvement of the Nrf2‐ARE Pathway. International Journal of Alzheimer’s Disease, 2011(1). https://doi.org/10.4061/2011/985085
Vancouver
Kanninen K, White AR, Koistinaho J, Malm T. Targeting Glycogen Synthase Kinase‐3 β for Therapeutic Benefit against Oxidative Stress in Alzheimer′s Disease: Involvement of the Nrf2‐ARE Pathway. International Journal of Alzheimer’s Disease. 2011;2011(1). doi:10.4061/2011/985085
BibTeX
@article{Kanninen2011,
author = {Kanninen, Katja and White, Anthony R and Koistinaho, Jari and Malm, Tarja},
title = {Targeting Glycogen Synthase Kinase‐3 β for Therapeutic Benefit against Oxidative Stress in Alzheimer′s Disease: Involvement of the Nrf2‐ARE Pathway},
journal = {International Journal of Alzheimer’s Disease},
year = {2011},
volume = {2011},
number = {1},
doi = {10.4061/2011/985085}
}
EUVIMED